A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: the AFR-15 trial.

摘要

This was a phase II investigation of high-dose imatinib in 15 adult patients with relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia (AML). Imatinib 600 mg daily was administered for 1 month followed by dose escalation to 800 mg daily for a maximum of 2 months. No clinical responses were reported with early death due to disease progression reported in 7 patients. While no activity was seen in this phase II trial, the findings of the study do not rule out efficacy in subsets of AML with imatinib-sensitive Kit mutations.